Annual Retained Earnings
-$457.47 M
-$21.43 M-4.91%
31 December 2023
Summary:
Y-mAbs Therapeutics annual retained earnings is currently -$457.47 million, with the most recent change of -$21.43 million (-4.91%) on 31 December 2023. During the last 3 years, it has fallen by -$172.27 million (-60.40%). YMAB annual retained earnings is now -1942.28% below its all-time high of -$22.40 million, reached on 31 December 2016.YMAB Retained Earnings Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Retained Earnings
-$480.35 M
-$7.00 M-1.48%
30 September 2024
Summary:
Y-mAbs Therapeutics quarterly retained earnings is currently -$480.35 million, with the most recent change of -$7.00 million (-1.48%) on 30 September 2024. Over the past year, it has dropped by -$23.86 million (-5.23%). YMAB quarterly retained earnings is now -1055.76% below its all-time high of -$41.56 million, reached on 31 December 2017.YMAB Quarterly Retained Earnings Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
YMAB Retained Earnings Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -4.9% | -5.2% |
3 y3 years | -60.4% | -58.2% |
5 y5 years | -439.3% | -236.6% |
YMAB Retained Earnings High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3 years | -60.4% | at low | -58.2% | at low |
5 y | 5 years | -439.3% | at low | -236.6% | at low |
alltime | all time | -1942.3% | at low | -1055.8% | at low |
Y-mAbs Therapeutics Retained Earnings History
Date | Annual | Quarterly |
---|---|---|
Sept 2024 | - | -$480.35 M(+1.5%) |
June 2024 | - | -$473.35 M(+2.0%) |
Mar 2024 | - | -$464.10 M(+1.4%) |
Dec 2023 | -$457.47 M(+4.9%) | -$457.47 M(+0.2%) |
Sept 2023 | - | -$456.48 M(+1.7%) |
June 2023 | - | -$448.74 M(+1.4%) |
Mar 2023 | - | -$442.43 M(+1.5%) |
Dec 2022 | -$436.04 M(+28.1%) | -$436.04 M(-0.3%) |
Sept 2022 | - | -$437.20 M(+6.7%) |
June 2022 | - | -$409.67 M(+11.2%) |
Mar 2022 | - | -$368.54 M(+8.2%) |
Dec 2021 | -$340.48 M | -$340.48 M(+12.2%) |
Sept 2021 | - | -$303.58 M(+10.5%) |
June 2021 | - | -$274.72 M(+9.1%) |
Date | Annual | Quarterly |
---|---|---|
Mar 2021 | - | -$251.79 M(-11.7%) |
Dec 2020 | -$285.20 M(+71.9%) | -$285.20 M(+7.5%) |
Sept 2020 | - | -$265.27 M(+14.1%) |
June 2020 | - | -$232.44 M(+21.0%) |
Mar 2020 | - | -$192.04 M(+15.8%) |
Dec 2019 | -$165.86 M(+95.5%) | -$165.86 M(+16.2%) |
Sept 2019 | - | -$142.73 M(+20.1%) |
June 2019 | - | -$118.81 M(+17.9%) |
Mar 2019 | - | -$100.77 M(+18.8%) |
Dec 2018 | -$84.83 M(+104.1%) | -$84.83 M(+19.9%) |
Sept 2018 | - | -$70.78 M(+19.3%) |
June 2018 | - | -$59.35 M(+42.8%) |
Dec 2017 | -$41.56 M(+85.5%) | -$41.56 M |
Dec 2016 | -$22.40 M | - |
FAQ
- What is Y-mAbs Therapeutics annual retained earnings?
- What is the all time high annual retained earnings for Y-mAbs Therapeutics?
- What is Y-mAbs Therapeutics annual retained earnings year-on-year change?
- What is Y-mAbs Therapeutics quarterly retained earnings?
- What is the all time high quarterly retained earnings for Y-mAbs Therapeutics?
- What is Y-mAbs Therapeutics quarterly retained earnings year-on-year change?
What is Y-mAbs Therapeutics annual retained earnings?
The current annual retained earnings of YMAB is -$457.47 M
What is the all time high annual retained earnings for Y-mAbs Therapeutics?
Y-mAbs Therapeutics all-time high annual retained earnings is -$22.40 M
What is Y-mAbs Therapeutics annual retained earnings year-on-year change?
Over the past year, YMAB annual retained earnings has changed by -$21.43 M (-4.91%)
What is Y-mAbs Therapeutics quarterly retained earnings?
The current quarterly retained earnings of YMAB is -$480.35 M
What is the all time high quarterly retained earnings for Y-mAbs Therapeutics?
Y-mAbs Therapeutics all-time high quarterly retained earnings is -$41.56 M
What is Y-mAbs Therapeutics quarterly retained earnings year-on-year change?
Over the past year, YMAB quarterly retained earnings has changed by -$23.86 M (-5.23%)